4887-24-5

Basic information

• Product Name: Triacetoxyboron
• Synonyms: Acetic acid boron;Triacetic acid boranetriyl ester;Triacetoxyborane;Triacetoxyboron
• CAS NO: 4887-24-5
• Molecular Formula: C₆H₉BO₆
• Molecular Weight: 187.9431
• Mol File: 4887-24-5.mol
• Article Data: 18

Chemical Properties

• Boiling Point: 209°Cat760mmHg
• Flash Point: 80.2°C
• Appearance: /
• Density: 1.174g/cm³
• Vapor Pressure: 2.1E-19mmHg at 25°C
• Refractive Index: 1.67
• CAS DataBase Reference: Triacetoxyboron(CAS DataBase Reference)
• NIST Chemistry Reference: Triacetoxyboron(4887-24-5)
• EPA Substance Registry System: Triacetoxyboron(4887-24-5)

Safety Data

• Hazardous Substances Data: 4887-24-5(Hazardous Substances Data)

Usage

General Description

Triacetoxyboron, also known as tributylborane or boron tributylate, is an organoboron compound that is often used as a catalyst in organic chemistry. It is a colorless, odorless liquid that is soluble in non-polar solvents such as hexane and ether. Triacetoxyboron has been used in various reactions such as hydroboration, reduction, and the synthesis of complex organic molecules. Its ability to selectively and effectively activate carbon-hydrogen bonds has made it a valuable tool in the development of new chemical compounds and materials. Additionally, triacetoxyboron has been investigated for its potential use in pharmaceutical chemistry and drug discovery due to its unique reactivity and selectivity.

InChI:InChI=1/C25H21N5O4/c1-32-18-7-8-19-20(12-18)29-24-23(19)27-15-30(25(24)31)28-13-16-6-9-21(33-2)17(11-16)14-34-22-5-3-4-10-26-22/h3-13,15,29H,14H2,1-2H3

Upstream product

• 11113-50-1 boric acid 
• 108-24-7 acetic anhydride 
• 121-43-7 Trimethyl borate 
• 64-19-7 acetic acid 
• 15243-31-9 Li{B(n-C₄H₉)4} 
• 4325-85-3 tris(trimethylsilyl)borate 
• 823-96-1 Trimethylboroxine 
• 1014979-56-6 5-ethyl-2-methylpyridine borane complex 
• 111-66-0 oct-1-ene 
• 2754-27-0 trimethylsilyl acetate 
• 369-57-3 benzenediazonium tetrafluoroborate 

Downstream Products

• 1693-71-6 tris(allyl)borate 
• 22238-17-1 tri-sec-butylborate 
• 37737-63-6 Tris(o-carboxylphenoxy)boran 
• 79-21-0 peracetic acid 
• 1615-02-7 p-chlorocinnamic acid 
• 830-09-1 3-(4'-methoxyphenyl)propenoic acid 
• 519-87-9 N,N-diphenylacetamide 
• 1927-95-3 4-bromophenyl acetate 
• 1200-06-2 4-methoxyphenyl acetate 
• 13031-41-9 4-cyanophenyl acetate 
• 140-11-4 Benzyl acetate 
• 24363-23-3 7-oxabicyclo[2.2.1]hept-2-ene-endo-5-carboxylic acid 
• 847449-75-6 triethylammonium tetracyanoborate 
• 139678-43-6 1-cyclopropyl-6,7-difluoro-8-methoxy-4-oxo-1,4-dihydro-3-quinoline carboxylic acid (O₃,O⁴)bis(acyloxy-O)borate 

Relevant articles and documents

Preparation method of moxifloxacin hydrochloride chelate

The invention provides a preparation method of moxifloxacin hydrochloride chelate, and belongs to the technical field of heterocyclic compound preparation. The preparation method comprises the following steps: keeping excessive acetic acid, adding trimethyl borate into the acetic acid, and reacting at 110-120 DEG C; after the reaction is finished, cooling, adding gatifloxacin intermediate, heatingto 110-120 DEG C after the addition is finished, keeping on reacting; recovering the fraction under reduced pressure until the reaction is finished, and recovering the solvent until the solvent is dry to obtain the chelate. The method has the advantages of simple process, economy, environmental friendliness and high product purity.

Preparation method of moxifloxacin hydrochloride

The invention discloses a preparation method of moxifloxacin hydrochloride. The method comprises the following steps: performing condensation by using 1-cyclopropyl-6,7-difluoro-1,4-dihydro-8-methoxy-4-oxo-ethylquinolinecarboxylate as a central ring, and (S,S)-2,8-diazabicyclo[4,3,0]nonane as a side chain, after alkali hydrolysis is completed, adding a part of 6N hydrochloric acid, performing primary crystallization, adding the remaining 6N hydrochloric acid, performing secondary crystallization, and performing recrystallization on the crystallized product obtain by the secondary crystallization once by using ethanol to obtain the moxifloxacin hydrochloride with a high content and excellent quality. When the method provided by the invention is adopted to prepare the moxifloxacin hydrochloride, product loss caused by repeated crystallization is reduced, labor intensity is reduced, energy consumption is reduced, product stability is improved, product quality is greatly improved, and themethod is suitable for industrialized large-scale production; and the prepared moxifloxacin hydrochloride contains 99.6%-102.0% of C21H25ClFN3O4 calculated by an anhydrate, and has a low total impurity content.

SOLID PHARMACEUTICAL COMPOSITION

[Problem] To provide a solid pharmaceutical composition which contains a compound represented by general formula (1) or a salt thereof and suppresses decomposition of said compound or salt thereof, and a production method of said solid pharmaceutical composition. [Solution] This solid pharmaceutical composition contains a compound represented by general formula (1) or a salt thereof, a cellulosic excipient, and an acidic substance of pH 4.0 or less.